SEC Form 4 · accession 0001012975-15-000498
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Nelsen
Director · 10% Owner
Period of report
Jun 18, 2015
Accepted (ET)
Jun 22, 2015 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jun 18, 2015 | J | 1,062,345 | — | D | 2,124,699 | I | See footnote |
| Common StockF1 | Jun 18, 2015 | J | 53,992 | — | A | 60,127 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Distribution of Common Stock held by a limited partnership to its partners for no consideration.
- F2ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH Venture Fund VII, L.P. ("ARCH"), may be deemed to beneficially own certain of the shares held by ARCH. The GPLP disclaims beneficial ownership of all shares held by ARCH in which the GPLP does not have an actual pecuniary interest. ARCH Venture Partners VII, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by ARCH. The GPLLC disclaims beneficial ownership of all shares held by ARCH in which it does not have an actual pecuniary interest. The managing directors of the GPLLC, the Reporting Person, Keith Crandell and Clinton Bybee (together, the "Managing Directors"), are deemed to have voting and dispositive power over the shares held by ARCH, and may be deemed to beneficially own certain of the shares held by ARCH.
- F3The Reporting Person disclaims beneficial ownership of all shares held by ARCH in which he does not have an actual pecuniary interest.
- F4Change from indirect to direct ownership of shares previously reported as beneficially owned by the reporting person